• LAST PRICE
    3.4500
  • TODAY'S CHANGE (%)
    Trending Down0.0000 (0.0000%)
  • Bid / Lots
    3.2600/ 10
  • Ask / Lots
    3.6500/ 3
  • Open / Previous Close
    3.4100 / 3.4500
  • Day Range
    Low 3.4100
    High 3.4800
  • 52 Week Range
    Low 2.6800
    High 8.3800
  • Volume
    27,231
    below average

Search Criteria

Filter search criteria using below inputs

Click on magnifying glass icon to search

Search Criteria - - - Stocks (0)
CompanyCountrySymbol
Select an index
Price Comparison Graph. See accessible table below
1 Day Comparison Chart Accessibility Table. Thursday's close: 3.45
TimeVolumeCALC
09:32 ET2833.41
09:33 ET1713.4272
09:35 ET12223.44
09:42 ET1003.45
09:50 ET2963.455
09:51 ET3113.46
09:53 ET21093.45
09:55 ET2003.46
10:00 ET1003.46
10:08 ET1003.45
10:11 ET4833.45
10:29 ET2063.45
10:36 ET8733.45
10:44 ET1003.45
11:23 ET1003.46
11:36 ET1073.465
11:56 ET1173.45
12:08 ET8003.45
12:19 ET1003.45
12:51 ET1003.45
01:11 ET2003.47
01:33 ET2503.46
01:56 ET4003.45
02:36 ET1003.4547
02:43 ET9753.45
02:59 ET6003.45
03:06 ET1003.45
03:28 ET5103.45
03:32 ET1713.46
03:46 ET3453.45
03:48 ET1003.45
03:50 ET50163.45
03:53 ET1003.46
03:55 ET36633.46
04:00 ET10263.45
Data delayed at least 15 minutes.
Industry Peers Overview Table
Company sortableMarket Cap sortableP/E Ratio (TTM) sortableEPS Growth (5yr) sortable
United StatesCALC
CalciMedica Inc
46.5M
-2.2x
---
United StatesIOBT
IO Biotech Inc
46.6M
-0.5x
---
United StatesOKYO
OKYO Pharma Ltd
35.5M
-1.5x
---
United StatesATNM
Actinium Pharmaceuticals Inc
45.2M
-1.0x
---
United StatesVICP
Vicapsys Life Sciences Inc
48.4M
-44.5x
---
United StatesGANX
Gain Therapeutics Inc
44.7M
-1.5x
---
As of 2024-11-23

Company Information

CalciMedica, Inc. is a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (CRAC) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses. The Company's technology targets the inhibition of CRAC channels to modulate the immune response and protect against tissue cell injury. Its lead product candidate is Auxora, a potent and selective intravenous (IV) formulated small molecule CRAC channel inhibitor containing the active compound zegocractin (formerly referred to as CM4620) that, in animal models, reduced acute epithelial and/or endothelial cell injury and inflammation in organs, such as the pancreas, lungs and kidneys. The Company is conducting a Phase 2b trial (called CARPO - NCT04681066) for acute pancreatitis (AP) with systemic inflammatory response syndrome (SIRS), as well as supporting the ongoing Phase 1/2 asparaginase induced pancreatic toxicity (AIPT) study (called CRSPA - NCT04195347).

Contact Information

Headquarters
505 Coast Boulevard South, Suite 307LA JOLLA, CA, United States 92037
Phone
858-952-5500
Fax
302-655-5049

Executives

Independent Chairman of the Board
Robert Wilson
President, Chief Operating Officer
Michael Dunn
Chief Executive Officer, Director
A. Rachel Leheny
Chief Financial Officer
Stephen Bardin
Chief Scientific Officer
Kenneth Stauderman

Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.

Open a New Account, or Login if you're a client.

You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.

Open a New Account, or Login if you're a client.

Fundamentals Table
Market Cap
$46.5M
Revenue (TTM)
$0.00
Shares Outstanding
13.5M
Dividend Yield
0.00%
Annual Dividend Rate
---
Ex-Dividend Date
01-01-01
Pay Date
01-01-01
Beta
1.23
EPS
$-1.57
Book Value
$1.43
P/E Ratio
-2.2x
Price/Sales (TTM)
---
Price/Cash Flow (TTM)
---
Operating Margin
---
*GAAP = prior to non-GAAP analyst adjusted earnings.

Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.

Open a New Account, or Login if you're a client.